---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125359"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:08:24.852419+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Artiva Q3 2024 net loss $17.5M; cash $199.6M; AlloNK data expected H1 2025

## Summary
- Net loss of $17.5M for Q3 2024 vs net income of $11.3M a year ago as collaboration revenue ended.
- Cash, equivalents and investments $199.6M at Sep 30, 2024; expected to fund operations through end of 2026.
- Completed upsized IPO in July 2024, gross proceeds $179.0M from 14.92M shares at $12.00.
- First patient dosed in AlloNK IIT for autoimmune diseases; initial Phase 1/1b and IIT data due H1 2025.
- Appointed Dr. Alison Moore to Board of Directors, bringing allogeneic cell therapy manufacturing expertise.

## SEC filing metadata
- accession: 0000950170-24-125359
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000095017024125359/0000950170-24-125359-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000095017024125359/artv-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125359
- JSON: https://secwatch.observer/filing/0000950170-24-125359.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125359.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.